While rescheduling cannabis to Schedule III might alleviate some challenges, Macias warns it could open the door for Big Pharma to monopolize the industry. “Rescheduling could push out the small ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback